Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Investing Activities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Cash from Investing Activities for 13 consecutive years, with -$276000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 89.96% year-over-year to -$276000.0, compared with a TTM value of -$21.9 million through Dec 2025, down 155.29%, and an annual FY2025 reading of -$21.9 million, down 155.29% over the prior year.
  • Cash from Investing Activities was -$276000.0 for Q4 2025 at Adma Biologics, up from -$14.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$276000.0 in Q4 2025 and bottomed at -$14.4 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$3.1 million, with a median of -$2.7 million recorded in 2021.
  • Peak annual rise in Cash from Investing Activities hit 89.96% in 2025, while the deepest fall reached 1208.56% in 2025.
  • Year by year, Cash from Investing Activities stood at -$3.7 million in 2021, then fell by 1.98% to -$3.7 million in 2022, then skyrocketed by 62.46% to -$1.4 million in 2023, then tumbled by 95.45% to -$2.8 million in 2024, then skyrocketed by 89.96% to -$276000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for ADMA at -$276000.0 in Q4 2025, -$14.4 million in Q3 2025, and -$2.5 million in Q2 2025.